ADTX — Aditxt, Inc.
$0.00
$-0.00 (-25.00%)
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.
Market Cap
$299392.00
Forward P/E
-0.0x
52-Week Range
N/A
ADTX Price History
Revenue vs. Net Income
$934K
Revenue · FY2022
Annual. Net margin is shown under each year.
Free Cash Flow
-$22.8M
FCF · FY2022
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-357.7%
ROCE · FY2022
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.9x
Assets ÷ liabilities · FY2022
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
39.3%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
10
Diluted shares · FY2022
Only one year of share data is available, so no change can be shown yet.
